Abstract
Most diseases affecting cows in the early stages of lactation are of an inflammatory nature and are associated with a decrease in reproductive function. Unfavorable environmental factors cause metabolic disorders, hormonal disorders and a decrease in the body's resistance. Favorable conditions are created for the development of opportunistic microflora in the reproductive organs of cows, causing inflammatory processes that can lead to infertility, decreased milk productivity and large economic losses. All this justifies the great interest shown in the study of obstetric and gynecological pathology by veterinary specialists, who consider the development and implementation of preventive and therapeutic measures to combat infertility as an urgent and serious task. Postpartum endometritis is a common disease in dairy herds. Antibiotics in treatment regimens become ineffective because pathogens infecting the uterine cavity develop resistance to them. Complex remedies are needed that have antiseptic, myotropic, wound healing and anti-inflammatory effects. A therapeutic veterinary drug «Endoseptam» has been developed, its high effectiveness in the prevention and treatment of endometritis has been proven. Studies are being conducted to establish the safety profile of the product. This article presents the results of studying the embryotoxic effect of the newly developed drug. White rats were used in the experiment. The drug was administered to laboratory animals per os at doses of 2000 mg/ kg and 20,000 mg / kg during 19 days of pregnancy. On the 20th day of pregnancy, some of the animals were euthanized and autopsied to assess the effects of «Endoseptam» on developing embryos/fetuses. The remaining part of the animals in the experiment was monitored to record the growth and development of offspring. The data obtained confirm the absence of toxic effects on developing embryos/fetuses of a complex remedy for the prevention and treatment of endometritis. When observing the physical development of offspring, there were no violations of embryonic development manifested in the postnatal period of life. The drug «Endoseptam» does not have an embryotoxic effect.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call